On Friday, Amedica Corporation (NASDAQ:AMDA)’s shares declined -10.03% to $0.270, while its weekly performance remained poor, showing the downward trend up to -12.90%, as Amedica Corporation (AMDA), declared its predictable participation in the following investor conference:
- 14th Annual Needham Healthcare Conference
- Tuesday, April 14, 2015
- 9:20 AM Eastern Time
- New York, NY
- Sonny Bal, Chairman and CEO, will conduct a formal presentation and take part in one-on-one meetings.
Amedica Corporation, a commercial-stage biomaterial corporation, develops, manufactures, and sells a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. It offers Valeo silicon nitride interbody spinal fusion devices for use in the cervical and thoracolumbar areas of the spine; and a line of non-silicon nitride spinal fusion products
Magnum Hunter Resources Corp (NYSE:MHR)’s shares dropped -1.59% to $2.48, during the last trading session on Friday, while its weekly performance remained poor, showing the downward trend up to -11.43%, as Magnum Hunter Resources Corp (MHR), declared that it has declared a monthly cash dividend on the Corporation’s 10.25% Series C Cumulative Perpetual Preferred Stock (“Series C Preferred Stock”), a monthly cash dividend on the Corporation’s 8.0% Series D Cumulative Preferred Stock (“Series D Preferred Stock”) and a monthly cash dividend on the Corporation’s 8.0% Series E Cumulative Convertible Preferred Stock (“Series E Preferred Stock”). The outstanding shares of Series E Preferred Stock are represented by depositary shares (the “Depositary Shares”), each representing a 1/1,000th interest of a share of Series E Preferred Stock.
The dividend on the Series C Preferred Stock, which is for the month of April 2015, is payable on April 30, 2015, to holders of record at the close of business on April 15, 2015. The payment will be an annualized 10.25% per share, which is equivalent to about $0.2135 per share, based on the $25.00 per share liquidation preference of the Series C Preferred Stock. The Series C Preferred Stock is presently listed on the NYSE MKT and trades under the ticker symbol “MHR.PRC”.
The dividend on the Series D Preferred Stock, which is for the month of April 2015, is payable on April 30, 2015, to holders of record at the close of business on April 15, 2015. The payment will be an annualized 8.0% per share, which is equivalent to about $0.3333 per share, based on the $50.00 per share liquidation preference of the Series D Preferred Stock. The Series D Preferred Stock is presently listed on the NYSE MKT and trades under the ticker symbol “MHR.PRD”.
Magnum Hunter Resources Corporation, an independent oil and gas corporation, explores for, exploits, attains, develops, and produces crude oil, natural gas, and natural gas liquid resources in the United States. The corporation operates through the U.S. Upstream, Midstream, and Oilfield Services segments. It operates in two of the unconventional shale resource plays in the United States, counting the Marcellus Shale and the Utica Shale plays located in the Appalachian Basin within the states of West Virginia and Ohio; and owns interests in non-operated oil and gas properties in the Williston Basin/Bakken Shale located in Divide County, North Dakota.
Receptos Inc (NASDAQ:RCPT), ended its Friday’s trading session with 2.44% up, and closed at $152.27, while its weekly performance remained poor, showing the downward trend up to -10.06%, after Receptos Inc (RCPT), declared that the Corporation has accomplished enrollment in the RADIANCE Phase 3 trial of ozanimod (formerly RPC1063) in patients with Relapsing Multiple Sclerosis (RMS). The trial was over-enrolled by about 10% due to strong interest among investigators and patients. The Corporation is ongoing to enroll the SUNBEAM trial of ozanimod in patients with RMS. Receptos is on track to complete this Phase 3 clinical development program in the first half of 2017.
“Concluding enrollment of the RADIANCE trial represents another major corporate milestone for Receptos, and positions ozanimod as the potential next-to-market oral agent for the treatment of relapsing multiple sclerosis,” said Faheem Hasnain, President and Chief Executive Officer of Receptos. “Following positive Phase 2 results in ulcerative colitis, we also plan to initiate a Phase 3 program for ozanimod in inflammatory bowel disease in 2015. We believe that ozanimod represents a potential franchise in immunology, and we continue to explore opportunities in other therapeutic indications where there is strong scientific rationale.”
The declaration follows the disclosure in September 2014 of the detailed Phase 2 results of ozanimod in RMS. In that trial, ozanimod met the primary endpoint of reduction in MRI brain lesion activity in addition to secondary endpoints measuring effects on other MRI parameters. The overall safety profile of ozanimod was comprising with the results of preceding trials and continues to be differentiated from other oral agents for the treatment of RMS.
Receptos, Inc., a clinical-stage biopharmaceutical corporation, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product comprises ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohns disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
